Research
Hormonal
The use of long‐acting incretin‐based therapies, such as semaglutide, has increased due to their benefits for glycemic control in diabetes, cardiovascular risk reduction, and weight management.
Clinicians should consider the benefits of semaglutide for patients with diabetes and weight management needs.
StrongSupportsmedium confidence
The use of long‐acting incretin‐based therapies, such as semaglutide, has increased in recent years due to their benefits for glycemic control in diabetes, cardiovascular risk reduction, and weight management.
Why this rating
The abstract discusses a review of existing literature.
Source
Legal, safety, and practical considerations of compounded injectable semaglutide
Allison Spitery et al. · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · 2024
DOI 10.1002/jac5.1999
reviewCited 8×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →